Autoimmune Hepatitis- Better
|
|
- Melanie Carroll
- 7 years ago
- Views:
Transcription
1 Autoimmune Hepatitis- Better Understanding 9 : 3 SG Maity, Kolkata Introduction & Definition Autoimmune Hepatitis () is generally considered un-resolving inflammation of liver of unknown cause. Pathologic mechanism postulates environmental triggers, failure of immune tolerance mechanisms, genetic pre-disposition collaborate to induce T-Cell mediated immune attack upon liver antigen leading to progressive necroinflammatory and fibrotic process in the liver (Figure 1). Onset is frequently insidious with non-specific symptoms such as fatigue, jaundice, nausea, abdominal pain and arthralgias, but clinical spectrum is wide ranging from asymptomatic presentation to an acute severe disease. Diagnosis is based on histologic abnormalities, characteristic clinical and laboratory findings, abnormal level of globulin and the presence of one or more characteristic auto antibodies. It is one of the important causes of chronic liver disease and diagnosed after exclusion of other causes like chronic viral hepatitis, wilson s disease, drug induced liver disease, NAFLD (Non alcoholic fatty liver disease), PBC (Primary biliary cirrhosis) and PSC (Primary sclerosing cholangitis). Diagnosis The diagnostic criteria for and diagnostic scoring system were co-defined by an international panel in 1993 and revised in The clinical criteria for the diagnosis are sufficient to make or exclude definite or probable in the majority of patients: Definitive diagnosis of : Require exclusion of other similar diseases, lab findings which indicate substantial immuno reactivity and on histology interface hepatitis. Probable diagnosis: It is justified when findings are compatible with but insufficient for definitive diagnosis. Patients who lack conventional autoantibody but who are seropositive for investigational markers e.g., Antibodies to ASGRP, SLA, actin or LC1, are classified as probable diagnosis. Diagnosis requires predominant elevation of serum aminotrans- ferase level, exclusion of other similar disorders (e.g., Wilson s disease, drug induced hepatitis and viral hepatitis), ANA (antinuclear antibody), SMA (smooth muscle antibody), anti-lkm1 (antibodies to liver kidney microsome type 1) Scoring Criteria: The original scoring system proposed by International Autoimmune Hepatitis group accommodates the diverse manifestation of and render an aggregate score that reflects the net strength of the diagnosis before and after glucocorticoid treatment (Table 1). A simplified scoring system has been developed to ease clinical application. The original scoring system has greater sensitivity for diagnosis than simplified system (100% vs. 95%) but the simplified system has greater specificity (90% vs. 73%) and predictability (92% vs. 82%). 463
2 Medicine Update 2012 Vol. 22 Elevated serum AST and gamma globulin levels AST: alkaline phosphatase >3 AMA negative Ceruloplasmin normal Normal α1 antitrypsin phenotype Normal or near-normal serum iron HBsAG, anti-hcv, IgM anti-hav negative Liver biopsy Interface hepatitis ± lobular hepatitis Definite Probable Gamma globulin level 1.5 normal ANA, SMA, or anti-lkm1 1:80 No exposure to drugs or blood products Alcohol intake < 25 g/day Gamma globulin level < 1.5 normal ANA, SMA, or anti-lkm1 1:40 Previous drugs or blood products Alcohol use Other liver- related auto antibodies Type 1 Type 2 ANA and/or SMA+ Anti-LKM1 + Fig. 1 : Diagnostic algorithm for 464
3 Autoimmune Hepatitis - Better Understanding Table 1 : Simplified scoring system for diagnosis of : Category Variable Score Auto antibodies ANA or SMA 1:40 +1 Antibodies to liver- kidney > 1:80 +2 microsome type 1 1:40 +2 Antibodies to soluble liver antigen Positive +2 Immunoglobulin Level Immunoglobulin G > upper limit of normal +1 1:1 times upper limit of normal +2 Histological findings Morphologic features Compatible with autoimmune hepatitis +1 Typical of autoimmune hepatitis +2 Viral Disease Absence of viral hepatitis No viral markers +2 Pre-treatment aggregate score Definite diagnosis 7 Probable diagnosis 6 Table 2 : Auto-antibodies in the diagnosis of : Antibody Target Antigen(s) Liver Disease Value in ANA Multiple targets including Chromatin Rhibo nucleoprotein Rhibo nucleoprotein complex PBC PSC Drug induced Chr. Hep C Chr. Hep B NAFLD SMA Microfilaments (filamentous action) LKM1 Cytochromac P-450 Type II Chr. Hep C panca Nuclear lamina Protein PSC Diagnosis of type I Diagnosis of type I Diagnosis of type II Diagnosis of type I SLA trnp Diagnosis of type I LKM3 Family I UDP Type II Gencoronosyc Transference (UGTIA) Diagnosis of type II ASGPR Asialoglycoprotein Prognostic implication Pathogenesis The pathogenic mechanism for is unknown. Popular hypothesis- includes triggering agent, genetic predeposition and various determinants of auto-antigen display, immunocyte activation, and effector cell expansion. Proposed triggering factor include infectious agent, drug and toxins. Clinical & Lab features Histology Treatment Table 3 : Variant forms of AH + PBC + PSC + Cholestatic features Features of AMA+ Cholangitis Cholestasis if AP 2x ULN & UDCA if AP>2x ULN and/or florid duct lesion. features ulcerative colitis AMA- Abnormal Cholangiogram Cholangitis Cholestasis & UDCA ANA and or SMA + AMA- No ulcerative colitis Normal cholangiogram Cholangitis Cholestasis and or UDCA depending on AP level & histology features. Auto-antibody negative features No autoantibody HLA-DR3 or DR4 Interface Hepatitis Conventional regimen for CD4+ helper T-Cell is the principle effector cell and its activation is the initial step in the pathogenic pathway. Classification- Two types of with distinct serologic profile have been identified (Table 2): Type I- Autoimmune Hepatitis- Type I is characterized by SMA, ANA or both. Antibodies to action have greater specificity but less sensitivity. A typical P-ANCA is found as many as 90% in type I. Type II- Autoimmune Hepatitis- Type II is characterized by the expression of Anti- LKM1. Most affected person is children between ages of 2 to 14 yrs. Variant Forms Patients who have atypical features of currently lack an official designation and confident treatment strategy (Table 3). Autoantibody- Negative Autoimmune hepatitis Thirteen percent of adult with chronic hepatitis of undermined cause satisfy international criteria for diagnosis of but lack of the characteristic auto-antibodies. These pts commonly designated as cryptogenic chronic hepatitis. Auto-antibody negative pts are similar in age, female predominant, frequency of concurrent immunology diseases, histologic features and laboratory findings of classic. They are similar frequency of HLA-B8, HLA-DR3 and HLA-A1 B8 DR3 and respond to glucocorticoid treatment. 465
4 Medicine Update 2012 Vol. 22 Table 4 : Clinical features Occurrence (%) Symptoms Fatigue 86 Jaundice 77 Upper abdominal discomfort 48 Pruritus (mild) 36 None (at presentation) Anorexia 30 Myalgias 30 Diarrhea 28 Cushingoid features 19 Fever ( 40 C) 18 Physical Findings Hepatomegaly Jaundice Spider angiomata Concurrent immune disease Splenomegaly None Ascites Encephalopathy Laboratory Features Elevated aspartate aminotransferase level Hypergammaglobulinemia Increased immunoglobulin G level Hyperbilirubinemia Alkaline phosphatase level 2-fold normal Immunoserologic Markers SMA, ANA, or anti-lkm1 Atypical panca Anti-asialoglycoprotein receptor Anti-actin Anti-chromatin Anti- liver cytosol 1 Anti- soluble liver antigen and Chronic hepatitis: < (type 1 only) (ANA+ only) 32 (type 2 only) About 8% of white North American adult with classic have concurrent HCV infection and 52% pts of chronic hepatitis C have auto-antibodies concurrent immune disease or both. It is important to identify to one or other group because interferon therapy can enhance immune manifestations of persons with and concurrent HCV infection and immunosuppressive treatment can increase serum viral level with chronic hepatitis C. Clinical features of - The clinical features of frequently reflect the inflammatory activity of the liver disease or complication of cirrhosis (Table 4). Severe or Fulminant presentation have an acute severe or fulminant presentation that can be mistaken for acute viral or toxic hepatitis and mis-diagnosis can delay life saving therapy. Glucocorticoid therapy can be effective in suppressing the inflammatory activity in % of pts, whereas delay in treatment lead to negative outcome. Treatment of (Table 5) A. Absolute indication of treatment Three randomized, controlled trails have demonstrated that pts with serum AST level at-least 10-fold of upper limit of normal (ULN) or more than 5-fold of ULN is associated with serum y-globulin level more than 2-fold ULN have high mortality (60% at 6 months), if untreated. Further histological findings of bridging necrosis or multilobular necrosis at presentation progress to cirrhosis is 82% in untreated pts and are associated with 5 yr mortality of 45%. These laboratory & histologic findings at presentation are absolute indication n of corticosteroid treatment. B. Uncertain indications In pts who have no or only mild symptoms and with mild lab & histologic findings & prospective & randomized controlled treatment trails not performed, their indication for treatment remains uncertain & highly unindividualized. Asymptomatic individuals with inactive cirrhosis may have an excellent immediate survival without corticosteroid treatment. There is no definite guideline to identify the safe population who require no therapy. Spontaneous resolution is possible in some asymptomatic pts with mild disease but these pts improve less commonly and more slowly than treated pts. Since mild autoimmune hepatitis can progress and a rapid & complete response to a normal end point can be anticipated, corticosteroid therapy is favored in asymptomatic mild disease, especially in young who can tolerate the medication satisfactorily. Corticosteroid therapy is effective only in pts with clinical, laboratory or histological features of active liver inflammation (Table 6). Pts with inactive or burned out cirrhosis cannot benefit from therapy and increased risk of drug-induced side effects. Pts with brittle diabetes, vertebral compression, pyschosis or severe osteoporosis must be critically analyzed for treatment benefit before corticosteroid administration. Treatment indication in children Treatments of children are similar to those of adults (Table 7). 466
5 Autoimmune Hepatitis - Better Understanding Table 5 : Indications for Treatment in Autoimmune Hepatitis Indications Findings Absolute Relative None Clinical Incapacitating symptoms Relentless clinical progression Mild or no symptoms Asymptomatic with minimal laboratory changes. Previous intolerance of prednisone and/or azathioprine Laboratory Histologic AST 10-fold ULN AST 5-fold ULN and gamma globulin 2-fold ULN Bridging necrosis Multilobular necrosis AST 3- to 9.9-fold ULN AST 5-fold ULN and gamma globulin <2-fold ULN Interface hepatitis AST <3-fold ULN Severe cytopenia Inactive cirrhosis Portal hepatitis Decompensated cirrhosis with vericeal bleeding. Prednisone only* (mg/ day) Prednisone* (mg/day) USA (mg/ day) EU (mg/kg/ day) Table 6 : Immunosuppressive Treatment Regimens for Adults in Monotherapy Combination Therapy Azathioprine Week Week Week Week Maintenance Until endpoint 20 and below Reasons for preference Cytopenia Post menopausal state Thiopurin methyltransferase deficiency Osteoporosis Brittle diabetes Obesity Pregnancy Acne Malignancy Emotional lability Shot course ( months) Hypertension * can be used in place of prednisone in equivalent doses. Treatment Regimens Treatment Regimen in Adults: Two treatment regimens are advocated and are equally effective in severe. Prednisone alone (60 mg daily), or lower dose of prednisone (30 mg daily) with azathioprine (50 mg daily or 1-2 mg/kg Table 7 : Immunosuppressive Treatment Regimens for Children in Initial Regimen Maintenance Regimen Endpoint Prednisone, 1.2 mg/kg Prednisone taper over 6 Normal liver tests for 1 daily (up to 60 mg/day), 8 weeks to mg/ 2 yrs during treatment. for two weeks either kg daily or 5 mg daily alone or in combination with azathioprine, 1.2 mg/kg daily. Azathioprine at constant No flare during entire dose if added ini- interval tially. Continue daily prednisone Liver biopsy examina- dose with or tion discloses no in- without azathioprine flammation. or switch alternate day prednisone dose adjusted to response with or without azathioprine body wt daily). Prednisone is tapered down to the individual sufficient to maintain remission with 20 mg daily, reduction of dose done by 5 mg every week until 10 mg/day and even further reduction of dose to 2.5 mg/week. The maintenance regimen is continued until resolution of disease, or treatment failure or drug intolerance. The combination of prednisone and azathioprine is associated with lower occurrence of corticosteroid related side-effects, than higher dose of prednisone & its preferred treatment. Treatment Regimen in Children: Treatment regimen is less rigorously established in children than adults & reflects the preferences of individual centres. But several report shows, children show similar efficacy as adults. Prednisone is the mainstay in virtually all reported regimen, at the dose of 1.2mg/kg of body wt daily. Tapering schedule vary widely. Recommendations Diagnosis of should be made when compatible clinical signs & symptoms, lab abnormalities, serological and histological findings are present and other conditions that can cause chronic hepatitis including viral, hereditary, metabolic, and cholestatic & drug induced disease have been excluded. Diagnostically challenging cases that have few or atypical clinical, laboratory, serological or histological findings should be assessed by the diagnostic scoring system. In pts negative for conventional auto-antibodies in is suspected, other serological marker e.g. Anti-SLA and atypical panca, should be tested. 467
6 Medicine Update 2012 Vol. 22 In pts with & multiple endocrine disorders, the APECED syndrome must be excluded by testing for typical mutation in the AIRE gene. Classification of into two types based on the presence of ANA and SMA (type 1 ) or anti-lkm1 and anti LCI (type 2 ) Diagnosis of should be considered in all pts with acute or chr. Hepatitis of undermined cause including pts with acute severe hepatitis. Cholangiographic studies should be considered to exclude PSC in adults if no response to corticosteroid therapy after 3 months. All children with and all adult with both & IBD should undergo cholangiographic studies to exclude PSC. Immunosuppressive treatment should be instituted in pts with serum AST or ALT level 10-fold ULN, at least 5-fold ULN in connection with serum x-globulin level, at-least 2-fold ULN, and/or histological features of bridging necrosis or multilobular necrosis. Immunosuppressive treatment may be considered in adult pts without symptoms & mild laboratory and histologic changes, but the decision is individualized & against possible risk. Immunosuppressive treatment should not be instituted in pts with minimal or no disease activity or inactive cirrhosis, but pts should follow closely. Immunosuppressive therapy should not be given in pts with serious pre-existent co-morbid condition (psychosis, vertebral compression, brittle diabetes, uncontrolled hypertension). Azathioprine should not be started in pts with severe pre-treatment cytopenia. Immunosuppressive treatment should be started in children at the time of diagnosis regardless of symptoms. Treatment should start with prednisone (starting with 30 mg daily & tapering down to 10 mg daily within 4 wks) in combination with azathioprine (50 mg daily or 1-2 mg/ kg body wt wkly. Combination regimen is preferred. In children prednisone (1-2 mg/kg daily, max 60 mg daily with azathioprine (1-2 mg/kg daily) or 6 mercaptopurine (1.5 mg/kg daily) Pts on long term corticosteroid should monitor for bone disease at base line and then annually & pre-treatment vaccination against HAV & HBV to be given. Pts to be counseled for risk of azathioprine in pregnancy & should be discontinued. Improvements of serum AST or ALT level, and also total bilirubin concentration & y-globulin or IgG level should be monitored at 3-6 months interval during treatment. Treatment should be continued until normal AST or ALT level, total bilirubin, y-globulin or IgG level and normal liver histology. 1 st relapse after drug withdrawal should be retreated with combination of prednisone plus azathioprine with same treatment regimen. Treatment failure in adults should be managed with high dose prednisone (60 mg daily) or 30 mg daily in combination with azathioprine (150 mg daily).other alternative medication e.g., mycofenolate mofetil, cyclosporine mycophenolate mofetil (2 gm daily orally) is the most promising agent. Liver transplantation should be considered in pts with acute liver failure, decompensated cirrhosis or HCC. References: 1. Alverez F, Berg P, Bianchi F et al, International Autoimmune Hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: Czaja AJ. Auto antibodies in autoimmune liver disease. Adv Clin Chem 2005; 40: Czaja AJ. Autoimmune hepatitis: Diagnosis. 4. Hennes EM, Zeniya M, Czaja AJ. Simplified diagnostic criteria for autoimmune hepatitis. Hepatology 2008; 48: Micheal P Mannas, Albert J Czaja, James D Gorhametal Hepatology, vol 51, No 6, AASLD Practice Guidelines, Diagnosis and management of Autoimmune hepatitis. 6. Sleisenger and Fordtran s Gastrointestinal and Liver disease. Pathophysiology/ Diagnosis/ Management 9e vol-2. Chap 88 P , Honnes EM, zenia M, Czaja AJ et al. Simplified diagnostic criteria for autoimmune hepatitis. Hepatology 2008; 48:
AASLD PRACTICE GUIDELINES Diagnosis and Management of Autoimmune Hepatitis
AASLD PRACTICE GUIDELINES Diagnosis and Management of Autoimmune Hepatitis Michael P. Manns, 1 Albert J. Czaja, 2 James D. Gorham, 3 Edward L. Krawitt, 4 Giorgina Mieli-Vergani, 5 Diego Vergani, 6 and
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function
More informationEvaluation of Liver Function tests in Primary Care. Abid Suddle Institute of Liver Studies, KCH
Evaluation of Liver Function tests in Primary Care Abid Suddle Institute of Liver Studies, KCH Liver Function tests Markers of hepatocellular damage Cholestasis Liver synthetic function Markers of Hepatocellular
More informationNP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
More information190.33 - Hepatitis Panel/Acute Hepatitis Panel
190.33 - Hepatitis Panel/Acute Hepatitis Panel This panel consists of the following tests: Hepatitis A antibody (HAAb), IgM antibody; Hepatitis B core antibody (HBcAb), IgM antibody; Hepatitis B surface
More informationApproach to Abnormal Liver Tests
Approach to Abnormal Liver Tests Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of Gastroenterology and Hepatology Indiana University School
More informationDrugs Believed Capable of Inducing Autoimmune Hepatitis
Drugs Believed Capable of Inducing Autoimmune Hepatitis Leonard B. Seeff, M.D. National Institutes of Diabetes and Digestive and Kidney Diseases National Institutes of Health Immune-Mediated Liver Diseases
More informationThe child with abnormal liver function tests
The child with abnormal liver function tests Dr Jane Hartley Consultant Paediatric Hepatologist Birmingham Children s Hospital, UK 1 st Global Congress CIP, Paris 2011 Contents Over view of liver anatomy,
More informationEvaluation of a Child with Elevated Transaminases. Linda V. Muir, M.D. April 11, 2008 Northwest Pediatric Liver Disease Symposium
Evaluation of a Child with Elevated Transaminases Linda V. Muir, M.D. April 11, 2008 Northwest Pediatric Liver Disease Symposium Disclosures I do not have a financial interest, arrangement or affiliation
More informationWhat to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon
What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon "it looks like there's something wrong.with your television set. Matt Groenig, creator of The Simpsons Probability of an abnormal screening
More informationEVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze
EVIDENCE BASED TREATMENT OF CROHN S DISEASE Dr E Ndabaneze PLAN 1. Case presentation 2. Topic on Evidence based Treatment of Crohn s disease - Introduction pathology aetiology - Treatment - concept of
More informationLCD for Viral Hepatitis Serology Tests
LCD for Viral Hepatitis Serology Tests Applicable CPT Code(s): 86692 Antibody; Hepatitis, Delta Agent 86704 Hepatitis B Core Antibody (HBcAb); Total 86705 Hepatitis B Core Antibody (HBcAb); IgM Antibody
More informationLiver Diseases. An Essential Guide for Nurses and Health Care Professionals
Brochure More information from http://www.researchandmarkets.com/reports/1047385/ Liver Diseases. An Essential Guide for Nurses and Health Care Professionals Description: Liver disease is a rapidly growing
More informationMolecular Diagnosis of Hepatitis B and Hepatitis D infections
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
More informationProf. of Tropical Medicine Faculty of Medicine Alexandria University
prof. Dr. Ali El-Kady (MD) Prof. of Tropical Medicine Faculty of Medicine Alexandria University DRUGS THAT MAY CAUSE LIVER DYSFUNCTION DAMAGE The liver is the principal organ that is capable of converting
More information2015 Outpatient Chronic Hepatitis B Management
2015 Outpatient Chronic Hepatitis B Management Hepatitis B Hepatitis B Info 70% of acute infections are subclinical More severe symptoms when in addition to other liver disease Fulminant Hepatitis
More informationThe Epidemiology of Hepatitis A, B, and C
The Epidemiology of Hepatitis A, B, and C Jamie Berkes M.D. University of Illinois at Chicago jberkes@uic.edu Epidemiology: Definitions The study of the incidence and prevalence of diseases in large populations
More informationHBV DNA < monitoring interferon Rx
Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute
More informationReview: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
More informationEvaluation of abnormal LFT in the asymptomatic patient. Son Do, M.D. Advanced Gastroenterology Vancouver, WA
Evaluation of abnormal LFT in the asymptomatic patient Son Do, M.D. Advanced Gastroenterology Vancouver, WA Definition of chronic, abnormally elevated LFT Elevation of one or more of the following for
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationBile Duct Diseases and Problems
Bile Duct Diseases and Problems Introduction A bile duct is a tube that carries bile between the liver and gallbladder and the intestine. Bile is a substance made by the liver that helps with digestion.
More informationCMS Limitations Guide - Laboratory Services
CMS Limitations Guide - Laboratory Services Starting October 1, 2015, CMS will update their exisiting medical necessity limitations on tests and procedures to correspond to ICD-10 codes. This limitattions
More informationAlanine aminotransferase (serum, plasma)
Alanine aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Alanine aminotransferase (ALT) 1.2 Alternative names Systematic name L alanine:2 oxoglutarate aminotransferase
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Hepatitis B Revised Hepatitis B 1.0 Provincial Reporting Confirmed, chronic and probable cases of disease
More informationLiver, Gallbladder and Pancreas diseases. Premed 2 Pathophysiology
Liver, Gallbladder and Pancreas diseases Premed 2 Pathophysiology Pancreas Pancreatitis Acute Pancreatitis Autodigestion of the pancreas due to activation of the enzymes Hemorrhagic fat necrosis, calcium
More information2.1 AST can be measured in heparin plasma or serum. 3 Summary of clinical applications and limitations of measurements
Aspartate aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Aspartate aminotransferase (AST) 1.2 Alternative names Systematic name L aspartate:2 oxoglutarate aminotransferase
More informationRheumatology Labs for Primary Care Providers. Robert Monger, M.D., F.A.C.P. 2015 Frontiers in Medicine
Rheumatology Labs for Primary Care Providers Robert Monger, M.D., F.A.C.P. 2015 Frontiers in Medicine Objectives Review the Indications for and Interpretation of lab testing for the following diseases:
More informationLIVER FUNCTION TESTS AND STATINS
LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationFast Facts. Fast Facts: Liver Disorders. Thomas Mahl and John O Grady. 2006 Health Press Ltd. www.fastfacts.com
Fast Facts Fast Facts: Liver Disorders Thomas Mahl and John O Grady 2006 Health Press Ltd. www.fastfacts.com Fast Facts Fast Facts: Liver Disorders Thomas Mahl MD University at Buffalo School of Medicine
More informationAlcoholic Hepatitis (Teacher s Guide)
Thomas Ormiston, M.D. Updated 5/5/15 2007-2015, SCVMC Alcoholic Hepatitis (Teacher s Guide) (30 minutes) I. Objectives Recognize the signs and symptoms of alcoholic hepatitis Understand the treatment options
More informationViral Hepatitis Case Report
Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date
More informationBritish Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis
British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis Dermot Gleeson, 1 Michael A Heneghan 2 Guidelines 1 Liver Unit, Sheffield Teaching Hospitals Foundation Trust,
More informationThe most serious symptoms of this stage are:
The Natural Progression of Hepatitis C The natural history of hepatitis C looks at the likely outcomes for people infected with the virus if there is no medical intervention. However, the process of trying
More informationLamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine
Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease From : New England Journal of Medicine Volume 351:1521-1531, Number 15, Oct 7, 2004 馬 偕 紀 念 醫 院 一 般 內 科, 肝 膽 腸 胃 科 新 竹 分 院 陳 重
More informationNUTRITION IN LIVER DISEASES
NUTRITION IN LIVER DISEASES 1. HEPATITIS: Definition: - Viral inflammation of liver cells. Types: a. HAV& HEV, transmitted by fecal-oral route. b. HBV & HCV, transmitted by blood and body fluids. c. HDV
More informationWhat to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning
More informationHEPATOLOGY CLERKSHIP
College of Osteopathic Medicine HEPATOLOGY CLERKSHIP Office for Clinical Affairs 515-271-1629 FAX 515-271-1727 Elective Rotation General Description This elective rotation is a four (4) week introductory,
More informationAlbumin. Prothrombin time. Total protein
Hepatitis C Fact Sheet February 2016 www.hepatitis.va.gov Laboratory Tests and Hepatitis If you have hepatitis C, your doctor will use laboratory tests to about learn more about your individual hepatitis
More informationLupus in Children and Teenagers. Arielle Hay, MD Pediatric Rheumatologist Nicklaus Children s Hospital
Lupus in Children and Teenagers Arielle Hay, MD Pediatric Rheumatologist Nicklaus Children s Hospital Systemic Lupus Erythematosus (SLE) Chronic Illness What is lupus? Autoimmune Multisystem Antinuclear
More informationIndications in Hepatology and Liver Diseases
exclusively working in Health Care sananet GmbH Tilo Stolzke Breite Str. 6-8 23562 Lübeck Germany Telefon : +49 451 400 8301 Telefax : +49 451 400 8302 E-Mail : stolzke@sananet.com Internet : www.sananet.com
More informationPhase: IV. Study Period: 20 Jan. 2006-17 Sep. 2008
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHepatitis C. Laboratory Tests and Hepatitis C
Hepatitis C Laboratory Tests and Hepatitis C If you have hepatitis C, your doctor will use laboratory tests to check your health. This handout will help you understand what the major tests are and what
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationAssessment of some biochemical tests in liver diseases
Assessment of some biochemical tests in liver diseases By Prof. Mohamed Sharaf-Eldin Prof. of Hepatology & Gastroenterology Faculty of Medicine Tanta University, Egypt. Significant liver damage may occur
More informationLAB 1 - Direct agglutination. Serology-the study of the in vitro reactions between antibody and antigen
LAB 1 - Direct agglutination Serology-the study of the in vitro reactions between antibody and antigen Serological reaction: - quantitative (weight/volume) - qualitative Agglutination - the aggregation
More informationHepatitis C Treatment Expansion Initiative Multi-Site Conference Call. March 16, 2011
Hepatitis C Treatment Expansion Initiative Multi-Site Conference Call March 16, 2011 Case Presentations Kansas City Free Health Clinic Carilion Clinic Didactic Session Challenges in Determining HCV Treatment
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationAbnormal Liver Function. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London
Abnormal Liver Function Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Does Liver Disease Matter? Mortality in England & Wales Liver-related
More informationAutoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationHepatology Guidelines for Primary Care November 2011
Common requests for hepatology opinion/advice 1. Abnormal LFTs (is this fatty liver?) 2. Fatty Liver Disease (is this serious liver disease?) 3. Abnormal liver ultrasound 4. Alcohol related liver disease
More informationSouthern Derbyshire. Shared Care Pathology Guidelines. Abnormal Liver Function Tests (LFTs) in Adults
Southern Derbyshire Shared Care Pathology Guidelines Abnormal Liver Function Tests (LFTs) in Adults Purpose of Guideline The management of patients with abnormal liver function test results Scope This
More informationThe following should be current within the past 6 months:
EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,
More informationAbnormal Liver Tests. Dr David Scott Gastroenterologist
Abnormal Liver Tests Dr David Scott Gastroenterologist Talk Outline Understanding Liver Tests Examples of Liver Diseases Case Studies Blood Tests for the Liver LFTs = Liver Function tests Hepatocyte damage
More informationLiver Failure. Nora Aziz. www.3bv.org. Bones, Brains & Blood Vessels
Liver Failure Nora Aziz www.3bv.org Bones, Brains & Blood Vessels Severe deterioration in liver function Looses ability to regenerate/repair decompensated Liver extensively damaged before it fails Equal
More informationAIR FORCE REPORTABLE EVENTS GUIDELINES & CASE DEFINITIONS
AIR FORCE REPORTABLE EVENTS GUIDELINES & CASE DEFINITIONS An Air Force addendum to the TRI-SERVICE REPORTABLE EVENTS GUIDELINES & CASE DEFINITIONS Prepared by: Air Force Institute for Operational Health
More informationHepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
More informationNovartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)
Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Highlights from Prescribing Information - the link to the full text PI is as follows: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf
More informationApproach to Abnormal Liver Tests
This Morning s Presentation Approach to Abnormal Liver Tests Hal F. Yee, Jr., M.D., Ph.D. Rice Distinguished Professor, UCSF Chief of Gastroenterology, SFGH hyee@medsfgh.ucsf.edu Clinical vignettes representing
More informationAfter the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
More informationAutoimmune Hepatitis/ Autoimmune Pancreatitis. Edmund Krasinski, Jr., D.O. F.A.C.G.
Autoimmune Hepatitis/ Autoimmune Pancreatitis Edmund Krasinski, Jr., D.O. F.A.C.G. Assessment of Liver Function Which of the following is not a good biochemical assessor of hepatic function? A) Serum bilirubin
More informationHOW TO EVALUATE ELEVATED LIVER ENZYMES
HOW TO EVALUATE ELEVATED LIVER ENZYMES Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine LABORATORY TESTS OF
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testing_serum_vitamin_d_levels 9/2015 2/2016 2/2017 2/2016 Description of Procedure or Service Vitamin D,
More informationBACKGROUND MEDIA INFORMATION Fast facts about liver disease
BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of
More informationService Definition with all Clinical Terms Service: Laprascopic Cholecystectomy Clinic (No Gallstones in bile duct)
Service Definition with all Clinical Terms Service: Laprascopic Cholecystectomy Clinic (No Gallstones in bile duct) Section 1 Service Details Service ID: 7540540 Service Comments: Referrer Alert: Service
More informationManaging LFT s in General Practice
Managing LFT s in General Practice Sulleman Moreea FRCP(Edin Edin) ) FRCS(Glasg Glasg) Consultant Gastroenterologist/Hepatologist Bradford Hospitals Trust The normal liver Managing LFT s History and examination
More informationSubproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases
Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases M. Trauner, Division of Gastroenterology and Hepatology, Department of Internal Medicine, MUG Co- Investigator: H. Samonigg,
More informationViral Hepatitis. 2009 APHL survey report
Issues in Brief: viral hepatitis testing Association of Public Health Laboratories May Viral Hepatitis Testing 9 APHL survey report In order to characterize the role that the nation s public health laboratories
More informationWhen an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
More informationHEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
More information12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS
HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE DISEASE 101 ONLINE CONFERENCE SARAH WENINGER, MPH VIRAL HEPATITIS.STD.HIV PREVENTION COORDINATOR DECEMBER 3, 2015 OBJECTIVES Describe the populations that should
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationChronic Hepatitis/Chronic Active Hepatitis in Dogs
Chronic Hepatitis/Chronic Active Hepatitis in Dogs Robert M. Hardy, DVM, MS, Diplomate ACVIM (Internal Medicine) Department of Small Animal Clinical Sciences College of Veterinary Medicine University of
More informationEvaluation and Prognosis of Patients with Cirrhosis
Evaluation and Prognosis of Patients with Cirrhosis Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded
More information190.25 - Alpha-fetoprotein
Other Names/Abbreviations AFP 190.25 - Alpha-fetoprotein Alpha-fetoprotein (AFP) is a polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More information1.5 Function of analyte For albumin, see separate entry. The immunoglobulins are components of the humoral arm of the immune system.
Total protein (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Total protein 1.2 Alternative names None 1.3 NMLC code 1.4 Description of analyte This is a quantitative measurement
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Multiple Technology Appraisal Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional
More informationAutoimmune Hepatitis. AIH: Clinical Features. Autoimmune Hepatitis (AIH) Core Curriculum In Hepatology And Liver Transplantation 2012-13
Core Curriculum In Hepatology And Liver Transplantation 2012-13 Autoimmune Liver Diseases: AIH, PBC, PSC November 20 th, 2012 Professor Suzanne Norris, PhD, FRCPI, Consultant Hepatologist, St. James Hospital,
More informationRecruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed
Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has
More informationNASH: It is not JUST a Fatty Liver. Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center
NASH: It is not JUST a Fatty Liver Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center Stages of Fatty Liver Disorders Fatty Liver 16-35% of Western
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationAdams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS
Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS Your health is important to us! The test descriptions listed below are for educational purposes only. Laboratory test interpretation
More informationTreatment of Acute Hepatitis C
Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Acute Hepatitis C Michael P. Manns, Andrej Potthoff, Elmar Jaeckel, Heiner Wedemeyer Hepatitis C Virus (HCV) infection is a common
More informationZika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases
Zika Virus Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases What is the incubation period for Zika virus infection? Unknown but likely to be several
More informationEASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version)
Journal of Hepatology 38 (2003) 533 540 Special article EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version) The EASL Jury*
More informationMANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol)
MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) 1. Hepatotoxicity: In Active TB Disease a. Background: 1. Among the 4 standard anti-tb drugs,
More informationThis regimen has low emetogenic potential refer to local protocol None required routinely. Baseline results valid for 7 days. Results valid for 72 hrs
Regimen : Ipilimumab for Advanced Melanoma ICD10 code Codes pre-fixed with C43. Indication Regimen detail Ipilimumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma
More informationHCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
More informationRecommendations for Early RA Patients
SUPPLEMENTARY APPENDIX 5: Executive summary of recommendations for patients with early RA, established RA, and high-risk comorbidities Recommendations for Early RA Patients We strongly recommend using
More informationAcute on Chronic Liver Failure: Current Concepts. Disclosures
Acute on Chronic Liver Failure: Current Concepts Vandana Khungar, MD MSc Assistant Professor of Medicine University of Pennsylvania, Perelman School of Medicine September 20, 2015 None to declare Disclosures
More informationUCLA Asian Liver Program
CLA Program Update Program Faculty Myron J. Tong, PhD, MD Professor of Medicine Hepatology Director, Asian Liver Program Surgery Ronald W. Busuttil, MD, PhD Executive Chair Department of Surgery Director,
More informationTREATING AUTOIMMUNE DISEASES WITH HOMEOPATHY. Dr. Stephen A. Messer, MSEd, ND, DHANP Professor and Chair of Homeopathic Medicine
TREATING AUTOIMMUNE DISEASES WITH HOMEOPATHY Dr. Stephen A. Messer, MSEd, ND, DHANP Professor and Chair of Homeopathic Medicine AUTOIMMUNE DISEASES An autoimmune disorder occurs when the body s immune
More informationAsymptomatic Elevated Liver Function Tests: Physiology, Chemistry, and Workup
Asymptomatic Elevated Liver Function Tests: Physiology, Chemistry, and Workup James T. Sing, Jr., D.O., FACG, AGAF Scott & White Clinic Assistant Professor Department of Internal Medicine Division of Gastroenterology
More informationAn overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More information